Catalio Capital Management, LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001958125

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q2 2025 · 40 positions · Total reported value $476.91M · Top-10 concentration 62.5% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 63.5% · 13 new · 14 cut · 6 exited

Active Share (vs S&P 500): 98.9% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q2 2025 13F filing, Catalio Capital Management, LP disclosed 40 equity positions with a combined reported value of $476.91M. The filing implies a focused portfolio: its ten largest positions account for 62.5% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2025 were LLY ($42.03M), BBIO ($40.06M), SLNO ($34.35M). By sector, the heaviest allocations are Health Care 92.6%, Other 7.4%. Versus the prior quarter, allocation shifted toward Health Care (+2.8pp) and away from Other (-2.8pp).

Versus the prior quarter, Catalio Capital Management, LP opened 13 new positions, trimmed 14 and fully exited 6, a turnover rate of 63.5% of positions. The portfolio's overlap with the prior quarter was 55% of names.

The largest new positions opened in Q2 2025 were GILD ($25.15M), BSX ($24.60M), TEVA ($19.62M).

Of the 6 positions fully exited versus the prior quarter, the largest were BDX ($46.72M), SWTX ($33.47M), VCYT ($22.60M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2025)

  • GILD GILEAD SCIENCES INC · $25.15M
  • BSX BOSTON SCIENTIFIC CORP · $24.60M
  • TEVA TEVA PHARMACEUTICAL INDS LTD · $19.62M
  • CORT CORCEPT THERAPEUTICS INC · $17.55M
  • NTRA NATERA INC · $16.44M
  • ADMA ADMA BIOLOGICS INC · $10.37M
  • HALO HALOZYME THERAPEUTICS INC · $9.96M
  • RARE ULTRAGENYX PHARMACEUTICAL IN · $7.76M

Fully Exited (vs previous quarter)

  • BDX BECTON DICKINSON & CO · prev qtr: $46.72M
  • SWTX SPRINGWORKS THERAPEUTICS INC · prev qtr: $33.47M
  • VCYT VERACYTE INC · prev qtr: $22.60M
  • LIVN LIVANOVA PLC · prev qtr: $14.99M
  • INSP INSPIRE MED SYS INC · prev qtr: $13.68M
  • REGN REGENERON PHARMACEUTICALS · prev qtr: $7.78M
  • KROS KEROS THERAPEUTICS INC · prev qtr: $3.97M
  • ARQT ARCUTIS BIOTHERAPEUTICS INC · prev qtr: $1.25M

Insider Transactions (Form 4)

Latest Catalio Capital Management, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-10-16 Conversion Iambic Therapeutics, Inc. 742,546 — SEC filing
2026-10-16 Conversion Iambic Therapeutics, Inc. 1,458,290 — SEC filing
2026-10-16 Conversion Iambic Therapeutics, Inc. 1,995,749 — SEC filing

All insider transactions →

Fund Profile

Catalio Capital Management, LP is an SEC-registered 13F filer based in New York, NY, United States. As of Q3 2026 it reported 46 US equity positions with a combined value of $535.82M. HoldingsHub carries 8 quarters of its filings (Q4 2024–Q3 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-121976 (status: Approved), registered 2021-07-30
  • Regulatory AUM (Form ADV): $1.93B as of 2026-03-31
  • Client mix (by RAUM): pension and profit-sharing plans 78%, pooled investment vehicles 13%
  • Manages 23 private funds, of which 1 hedge funds

Portfolio Structure

  • 46 positions · $535.82M reported value (Q3 2026)
  • Top 10 holdings = 48.7% of reported value
  • Largest position: AVLN (AVALYN PHARMACEUTICALS INC) at 9.0%
  • Average position size: $11.65M

Sector Tilt

  • Health Care 96.3%
  • Industrials 2.8%
  • (classified holdings cover 99% of value)

Quarterly Activity

  • Q3 2026: 13 new, 13 added, 14 reduced, 6 exited
  • 6 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 92.6%
Other 7.4%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 53.92K $42.03M 8.81%
8.81%
Add
2 927.71K $40.06M 8.40%
8.40%
Reduce
3 409.94K $34.35M 7.20%
7.20%
Add
4 179.93K $31.06M 6.51%
6.51%
Reduce
5 56.67K $30.80M 6.46%
6.46%
Add
6 390.93K $30.57M 6.41%
6.41%
Reduce
7 226.88K $25.15M 5.27%
5.27%
New
8 229.05K $24.60M 5.16%
5.16%
New
9 601.44K $19.87M 4.17%
4.17%
Add
10 2.10M $19.71M 4.13%
4.13%
Add
11 1.17M $19.62M 4.11%
4.11%
New
12 239.12K $17.55M 3.68%
3.68%
New
13 97.30K $16.44M 3.45%
3.45%
New
14 1.40M $16.27M 3.41%
3.41%
Add
15 746.53K $13.91M 2.92%
2.92%
Reduce
16 670.58K $13.91M 2.92%
2.92%
Reduce
17 569.70K $10.37M 2.17%
2.17%
New
18 191.53K $9.96M 2.09%
2.09%
New
19 213.40K $7.76M 1.63%
1.63%
New
20 162.60K $7.67M 1.61%
1.61%
Add
21 672.29K $6.45M 1.35%
1.35%
New
22 417.44K $5.82M 1.22%
1.22%
Reduce
23 61.51K $5.68M 1.19%
1.19%
New
24 1.63M $4.93M 1.03%
1.03%
Add
25 166.67K $3.20M 0.67%
0.67%
Hold
26 294.36K $3.11M 0.65%
0.65%
Reduce
27 330.34K $3.07M 0.64%
0.64%
Reduce
28 215.31K $2.09M 0.44%
0.44%
Reduce
29 388.30K $1.96M 0.41%
0.41%
Reduce
30 586.91K $1.80M 0.38%
0.38%
Hold
31 30.66K $1.62M 0.34%
0.34%
New
32 188.30K $1.30M 0.27%
0.27%
Reduce
33 97.80K $908.56K 0.19%
0.19%
New
34 528.99K $782.91K 0.16%
0.16%
Hold
35 146.01K $629.32K 0.13%
0.13%
Reduce
36 760.03K $546.92K 0.12%
0.12%
Hold
37 1.57M $463.95K 0.10%
0.10%
Reduce
38 196.86K $431.12K 0.09%
0.09%
Hold
39 214.24K $347.06K 0.07%
0.07%
Hold
40 14.72K $126.28K 0.03%
0.03%
New

FAQ

What did Catalio Capital Management, LP buy in 2025-Q2?

In its 2025-Q2 13F filing, Catalio Capital Management, LP reported 40 equity positions worth $476.91M in aggregate; its largest disclosed positions were LLY ($42.03M), BBIO ($40.06M), SLNO ($34.35M).

How large is Catalio Capital Management, LP's portfolio?

Catalio Capital Management, LP reported $476.91M of long equity holdings across 40 positions as of 2025-Q2. Top-10 holdings account for 62.5% of reported value.

What is Catalio Capital Management, LP's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/catalio-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →